Skip to main content

Table 6 The correlation between CSC marker levels in sera with clinicopathological features and laboratory results in early stage CCA patients

From: Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

Variables

Early stage (TNM stage I, II)

n

CD44

p

CD44v6

p

CD44v8-10

p

EpCAM

p

Sex

 Female

22

0.47 ± 0.13

 

0.80 ± 0.17

 

0.70 ± 0.13

 

0.46 ± 0.16

 

 Male

38

0.51 ± 0.16

0.306

0.79 ± 0.18

0.861

0.70 ± 0.15

0.913

0.48 ± 0.15

0.623

Age (year)

 Less than 61

30

0.51 ± 0.15

 

0.82 ± 0.15

 

0.72 ± 0.12

 

0.50 ± 0.15

 

 61 or greater

30

0.49 ± 0.16

0.579

0.77 ± 0.20

0.220

0.68 ± 0.17

0.276

0.44 ± 0.16

0.102

Tumor site

 Intrahepatic

31

0.50 ± 0.13

 

0.80 ± 0.15

 

0.71 ± 0.13

 

0.47 ± 0.13

 

 Extrahepatic

29

0.49 ± 0.18

0.888

0.79 ± 0.20

0.778

0.70 ± 0.17

0.710

0.47 ± 0.18

0.928

Histology type

 Papillary

38

0.52 ± 0.13

 

0.82 ± 0.14

 

0.72 ± 0.13

 

0.48 ± 0.16

 

 Others

22

0.47 ± 0.18

0.229

0.74 ± 0.21

0.079

0.68 ± 0.17

0.277

0.45 ± 0.16

0.449

Tumor marker

 CA19-9 (U/mL)

         

  < 37

24

0.44 ± 0.13

 

0.77 ± 0.16

 

0.67 ± 0.14

 

0.40 ± 0.11

 

  ≥ 37

21

0.57 ± 0.15

0.006

0.85 ± 0.13

0.072

0.77 ± 0.10

0.011

0.54 ± 0.14

< 0.001

 CEA (ng/mL)

  < 2.5

16

0.48 ± 0.12

 

0.81 ± 0.15

 

0.70 ± 0.14

 

0.44 ± 0.12

 

  ≥ 2.5

30

0.52 ± 0.16

0.405

0.81 ± 0.15

0.937

0.72 ± 0.13

0.653

0.48 ± 0.15

0.286

 AFP (IU/mL)

  < 5

33

0.48 ± 0.15

 

0.79 ± 0.14

 

0.70 ± 0.13

 

0.45 ± 0.14

 

  ≥ 5

4

0.55 ± 0.21

0.387

0.80 ± 0.14

0.894

0.71 ± 0.13

0.937

0.50 ± 0.21

0.553

Liver function test

 Direct bilirubin (mg/dL)

  < 1.5

35

0.48 ± 0.14

 

0.79 ± 0.15

 

0.69 ± 0.13

 

0.44 ± 0.13

 

  ≥ 1.5

18

0.53 ± 0.19

0.261

0.79 ± 0.22

0.937

0.71 ± 0.18

0.600

0.49 ± 0.17

0.276

 Total bilirubin (mg/dL)

  < 2.5

33

0.49 ± 0.14

 

0.80 ± 0.15

 

0.70 ± 0.14

 

0.46 ± 0.13

 

  ≥ 2.5

22

0.51 ± 0.18

0.571

0.78 ± 0.21

0.696

0.70 ± 0.17

0.866

0.46 ± 0.17

0.992

 ALT (U/L)

  < 40

30

0.50 ± 0.14

 

0.81 ± 0.16

 

0.73 ± 0.12

 

0.46 ± 0.11

 

  ≥ 40

23

0.48 ± 0.18

0.521

0.75 ± 0.19

0.238

0.66 ± 0.17

0.089

0.46 ± 0.19

0.888

 AST (U/L)

  < 40

28

0.48 ± 0.13

 

0.79 ± 0.16

 

0.70 ± 0.13

 

0.47 ± 0.13

 

  ≥ 40

25

0.50 ± 0.18

0.709

0.78 ± 0.19

0.794

0.69 ± 0.17

0.752

0.46 ± 0.17

0.834

 ALP (U/L)

  < 130

18

0.45 ± 0.15

 

0.76 ± 0.16

 

0.68 ± 0.13

 

0.42 ± 0.12

 

  ≥ 130

35

0.52 ± 0.16

0.129

0.80 ± 0.18

0.479

0.71 ± 0.16

0.575

0.48 ± 0.16

0.151

  1. CD44 cluster of differentiation 44, CD44v CD44 variant, EpCAM epithelial cell adhesion molecules, TNM primary tumor-node-metastasis, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us